Hydration and constipation on a GLP-1: the kidney warning behind the water advice, and a constipation plan with sources

"Drink more water" is the advice everyone on a GLP-1 receives and almost nobody is told the reason for. The reason is on the label, and it is not about weight loss or skin. This guide starts with the kidney warning, then deals with the other consequence of eating and drinking less on a slower gut: constipation, which affects roughly one in four people on semaglutide and one in six on tirzepatide.

The kidney warning

Every one of the four labels contains a section headed acute kidney injury (Wegovy 5.5, Zepbound 5.3, Ozempic 5.6, Mounjaro 5.5). The text is consistent: there have been postmarketing reports of acute kidney injury, in some cases requiring haemodialysis, in patients treated with GLP-1 receptor agonists. The majority of the reported events occurred in patients who experienced nausea, vomiting, diarrhoea or dehydration. Some occurred in patients with no known underlying kidney disease. The instruction to clinicians is to monitor renal function when starting or escalating in patients with kidney impairment who report severe GI reactions.

The chain is simple. GI adverse effects cause fluid loss, fluid loss reduces blood flow to the kidneys, and kidneys with reduced blood flow can be injured, particularly if they were already impaired or if the person takes other drugs that stress them (the labels do not list these, but diuretics, ACE inhibitors, ARBs and NSAIDs are the usual clinical concern). Water does not prevent nausea. It replaces what vomiting and diarrhoea take out, which is the point.

How much to drink

The labels give no figure. The clinical recommendations papers (Gorgojo-Martinez 2022, PubMed 36614945; Wharton 2022, PubMed 34775881) advise regular fluid intake through the day, increased when GI symptoms are active, and small frequent sips rather than large volumes when nauseated. That is the extent of the published guidance.

A practical approach: aim for pale straw-coloured urine; carry a bottle and drink between meals rather than with them (large volumes with food worsen fullness and reflux); increase intake on hot days, after exercise, and in the week after a dose increase; and treat an inability to keep fluids down as a medical problem, not a hydration problem. People on the drug often stop feeling thirsty as their appetite drops, so a schedule works better than waiting for thirst.

Electrolyte drinks have a place during active vomiting or diarrhoea, where the loss is not only water. Outside those episodes, water is enough for most people; the labels say nothing about electrolytes.

When fluid loss becomes an emergency

Persistent vomiting or diarrhoea with any of: passing much less urine than usual, dark urine, dizziness or fainting on standing, confusion, a racing heart, or being unable to keep fluids down for more than a day. These are the signs of significant volume depletion, and with the label's kidney warning behind them they warrant same-day medical assessment. Do not wait for the next appointment. If you have known kidney disease, the threshold is lower still.

Constipation: the numbers

The Wegovy label's adverse reaction table reports constipation in 24 percent of adults on 2.4 mg versus 11 percent on placebo. The Zepbound label reports 17, 14 and 11 percent at 5, 10 and 15 mg versus 5 percent on placebo; the falling rate at higher doses reflects that diarrhoea rises with dose, not that constipation improves. Both labels list it among the most common reactions and describe the GI effects overall as mostly mild to moderate.

Why it happens

Three things combine. GLP-1 receptor activation slows transit through the gut, which is the same effect that slows gastric emptying. Reduced food intake means less fibre and less bulk reaching the colon. Reduced fluid intake means the colon, which reclaims water from stool, is working with less. The labels do not state a mechanism; this is the physiological account given in the clinical recommendations papers.

A constipation plan, in order

The AGA/ACG 2023 clinical practice guideline on chronic idiopathic constipation (Chang 2023, PubMed 37211380) is the most rigorous source available; it was written for constipation in general rather than for GLP-1 users, so this is general practice applied to the situation.

Fluids and movement first. The two things this guide has already argued for. Walking after meals is the simplest transit aid there is.

Fibre. The guideline suggests fibre supplementation, and psyllium specifically, as a first step, with the caveat that it must be taken with adequate water or it makes things worse. Increase gradually; a sudden jump in fibre on a slow gut produces bloating and gas, which are already label-listed effects. Food sources count: oats, fruit with skin, vegetables, beans, and enough of them, which on a suppressed appetite takes deliberate effort.

Osmotic laxatives. The guideline recommends polyethylene glycol (PEG 3350) as a first-line pharmacological option, with a strong recommendation, and lactulose and magnesium-based products as alternatives. These draw water into the stool and are suitable for regular use if needed. The GLP-1 labels list no interaction with any of them.

Stimulant laxatives. Senna and bisacodyl are recommended by the guideline for short-term or rescue use when osmotic agents are insufficient. They are not a long-term first choice.

Prescription options. The guideline covers secretagogues (lubiprostone, linaclotide, plecanatide) and prucalopride for constipation that does not respond to the above. These are prescriber decisions.

Tell your prescriber. Constipation that persists despite the first three steps, or that is severe, belongs in the conversation about dose: the label's option to delay escalation or settle on a lower maintenance dose applies to any GI adverse reaction, not only nausea. The dose escalation guide explains how to raise it.

Constipation that is something else

Constipation with severe abdominal pain and vomiting, a swollen tender abdomen, or no wind passed at all is a possible bowel obstruction and needs urgent care; the postmarketing sections of the Wegovy and Zepbound labels list ileus, intestinal obstruction and severe constipation including faecal impaction. Blood in the stool, unexplained weight loss beyond what the drug is producing, or a change in bowel habit in someone over 50 who has not had screening are reasons to be assessed regardless of the GLP-1. Constipation alternating with diarrhoea over weeks is worth mentioning too.

A daily routine that covers both

A glass of water on waking and one before each meal, the bottle refilled at least twice through the working day, and a check on urine colour mid-afternoon. Fibre at breakfast (oats, fruit) and a vegetable or pulse with the two other meals, increased over two weeks rather than overnight. A ten-minute walk after the largest meal. Psyllium in a full glass of water in the evening if stools have been hard for more than a few days, and polyethylene glycol from the pharmacy if that has not worked within a week. In the week after a dose increase, add a glass of water to each of those points and expect the routine to matter more, not less. None of this is on the label; all of it is consistent with the guidance cited above and costs nothing to try.

Protein and fibre together

The muscle preservation guide argues for a higher protein intake on a GLP-1. Protein-heavy, fibre-poor eating is a reliable route to constipation; the two goals have to be planned together, which is easier when total intake is small. A protein target calculator that also shows fibre is on the calculator site.

Compounded products

Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with brand products, and no adverse-event table exists for them; the rates above are the brand-label rates for the same active ingredients. The kidney warning applies with equal force. FormBlends describes what its pharmacies dispense on its semaglutide and tirzepatide pages.